Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses current therapeutic options for younger patients with acute myeloid leukemia. Dr Fathi notes that the approved guidance for azacitidine or decitabine plus venetoclax is limited to patients who are ineligible for intensive chemotherapy or older patients. For younger patients, a less-intensive approach may be considered, especially in cases of highly resistant p53-mutated disease.